KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.

Namasivayam Ambalavanan, Waldemar A Carlo, Kayla J Nowak, Laura Elizabeth Wiener, Shirley S Cosby, Abhay J Bhatt, Kristi L Watterberg, Brenda B Poindexter, Martin Keszler, Carl T D'Angio, Luc P Brion, Vivek Narendran, Carrie A Rau, C Michael Cotten, Matthew M Laughon, Abhik Das, Matthew A Rysavy, Anna Maria Hibbs, Janell Fuller, Karen M Puopolo, Anup Katheria, Ravi M Patel, Jennifer R Bermick, Abbot R Laptook, Irina Prelipcean, Myra H Wyckoff, Ryan Moore, Stephanie L Merhar, Robin K Ohls, Bradley A Yoder, Marta Perez, Sarvin Ghavam, Lauritz R Meyer, Valerie Y Chock, Sara B DeMauro, Wesley M Jackson, Deepali Handa, Michele C Walsh, National Institute of Child Health and Human Development Neonatal Research Network

JAMA 334(16) 1452-1462

PMID41026481
PMCIDPMC12486137
DOI10.1001/jama.2025.16450
发表日期2025-09-30
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:森林图/亚组分析图。
摘要

摘要

IMPORTANCE: Extremely preterm infants are at high risk for bronchopulmonary dysplasia (BPD) and death. Multiple small randomized clinical trials showed that a combination of budesonide with surfactant compared with surfactant alone reduced BPD or death. OBJECTIVE: To determine if early intratracheal administration of a combination of budesonide (0.25 mg/kg) mixed with surfactant, compared with surfactant alone, reduces physiologic BPD or death by 36 weeks' postmenstrual age in extremely preterm infants. DESIGN, SETTING, AND PARTICIPANTS: This double-masked randomized clinical trial was conducted from April 2021 to June 2024 in the 17 centers of the United States Neonatal Research Network. Infants 22 to 28 weeks' gestation or 401 to 1000 g birth weight were enrolled after clinical decision to give surfactant, with the first dose of surfactant being study drug (prior surfactant was an exclusion criterion). INTERVENTIONS: Infants were randomly allocated 1:1 to receive 1 to 2 doses of budesonide + surfactant (poractant alfa) or surfactant alone via endotracheal tube within 50 hours of birth. MAIN OUTCOMES AND MEASURES: The primary outcome was physiologic BPD or death by 36 weeks' postmenstrual age. There were 5 prespecified secondary outcomes and multiple prespecified exploratory and safety outcomes. RESULTS: The trial was stopped with 641 infants enrolled (55.3% of 1160 planned; mean birth weight, 810 g [SD, 256 g]; gestational age, 25.9 weeks [SD, 1.9 weeks]), because interim analysis at 50% enrollment reached the prespecified futility threshold. The incidence of BPD or death was 68.5% in the budesonide + surfactant group and 67.9% in the surfactant-alone group (adjusted relative risk [RR], 1.00 [95% CI, 0.90-1.11]). No differences were noted in mortality (15.3% vs 13.2%; adjusted RR, 1.13 [95% CI, 0.78-1.64]) or BPD among survivors to 36 weeks' postmenstrual age (62.9% vs 63.0%; adjusted RR, 0.99 [95% CI, 0.87-1.12]). More infants who received budesonide + surfactant compared with surfactant alone had hyperglycemia (66.7% vs 49.8%; adjusted RR, 1.33 [95% CI, 1.17-1.51]). CONCLUSIONS AND RELEVANCE: In this large multicenter trial, the combination of budesonide with surfactant did not reduce the risk of BPD or death at 36 weeks' postmenstrual age in extremely preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04545866.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Study Flow for a Trial of Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants a Assessments of eligibility include antenatal screenings of mothers (n = 4042) and postnatal screenings of infants (n = 1311). Families who declined consent antenatally or who consent antenatally but delivered out of gestational age window were each captured once, regardless of single or multiple gestation. b Reasons for ineligibility include prior use of surfactant (1356), no clinical decision to give surfactant (811), gestational age and/or birth weight outside eligibility window (387), prior indomethacin use (224), terminally ill or a decision to redirect support (193), serious chromosomal abnormality or neuromuscular condition (138), more than 48 hours’ postnatal age at time of randomization (59), enrolled in a conflicting trial (58), stillbirth (47), prior use of systemic steroids (20), and known congenital infection (15). Multiple reasons for ineligibility may be provided. c A total of 815 parents declined consent antenatally and prior to assessment of infant eligibility; 453 parents declined consent postnatally, of which 399 infants were eligible and 54 had not been assessed for eligibility. d Other reasons not enrolled include passive nonconsent (eg, parent/guardian no decision, not approached, or unavailable), physician decision not to consent and/or enroll, or logistic barriers to the consent and/or enrollment process (eg, staff availability, drug kit availability, urgent delivery, parent/guardian did not speak English, early study closure). e One infant was randomized and treated in error after the parent/guardian declined consent. The infant was withdrawn from the trial on discovery of the protocol violation. At the parent’s request, the infant’s data have been fully redacted. No data are available for reporting or analysis (including treatment allocation), and this participant is excluded from the intention-to-treat population. f Participants who received budesonide with surfactant for either or both doses of study drug are considered to be treated under the budesonide + surfactant group. g One infant died prior to treatment; 1 became too medically unstable to participate; 1 was ineligible and randomized in error. h Two infants improved and did not require surfactant; one was ineligible and randomized in error. i In addition to the withdrawn infant (see footnote “e”), 2 randomized infants withdrew prior to primary end point assessment. One infant was randomized and treated without consent (parent/guardian declined consent to continue). The other infant was ineligible and randomized in error (not treated); effectively withdrawn since they were also ineligible for the Generic Data Base data collection. j The primary analysis was performed for the intention-to-treat analysis population, and the model excluded participants missing the primary end point (2). This model was repeated for 2 analysis subpopulations as a planned sensitivity analysis. The intention-to-treat analysis excluding untreated participants also excluded participants who were not treated (5). The per-protocol analysis also excluded participants who either were not treated (5) or had a major treatment protocol violation (5 ineligible enrollments; 4 treated under the wrong group or both groups; 3 received more than 2.4 times the intended dose; 2 received less than one-half of the intended dose; 1 treated after the dosing window; and 2 other dosing administration violation).
非 KM Figure
Figure 2Figure 2.. Survival Without Physiologic Bronchopulmonary Dysplasia at 36 Weeks’ Postmenstrual Age by Subgroup in the Intention-to-Treat Population Subgroup analyses considered relative risk of a favorable outcome (alive and without physiologic bronchopulmonary dysplasia) at 36 weeks’ postmenstrual age, comparing the budesonide + surfactant group with the surfactant-alone group. Relative risks and 95% CIs were estimated using robust Poisson regression. The gestational age subgroup models adjusted for pooled center; all other models adjusted for gestational age strata and pooled center. All analyses were performed at the α = .05 significance level for descriptive purposes only. F io 2 indicates fraction of inspired oxygen. a Reflects actual gestational age (best clinical estimate), regardless of randomization strata. b Histological or clinical. c Refers to the last known level of respiratory support prior to treatment initiation. The F io 2 subgroups exclude 182 participants from the intention-to-treat population who do not have baseline respiratory data. Most of the excluded participants (138, 76%) initiated treatment within 30 minutes of birth. d Includes self-reported American Indian or Alaska Native, Asian, Native Hawaiian or Other Pacific Islander, or more than 1 race.
非 KM Figure